Imagion Expands Collaboration with Siemens Healthineers to United States

NEW YORK, June 29, 2023--(BUSINESS WIRE)--Manhattan Scientifics Inc. (OTC: MHTX ), announces that Siemens & Imagion Biosystems (IBX:ASX) collaborate.

U.S. Founder MHTX owns 50 million Shares of Imagion Biosystems.

For further details, please see Imagion Biosystems Press Release

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. (www.mhtx.com) is focused on technology transfer and commercialization of transformative technologies.

About Imagion Biosystems

Imagion Biosystems (www.imagionbiosystems.com) is developing a new non-radioactive and super-sensitive diagnostic imaging technology for very early detection of cancers. Imagion is listed on the Australian Stock Exchange (ASX).

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230629885280/en/

Contacts

Manhattan Scientifics, Inc.
Manny Tsoupanarias, 917-688-4158
Manny@mhtx.com
Or
Marvin Maslow, 917-923-3300
Marvin@mhtx.com